/ SPARC Soars 3.7% Gets Complete Esponse Letter From USFDA For Xelpros ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Thursday, 22 December 2016

Sun Pharma Advanced Research Company Ltd is currently trading at Rs 319.4, up by Rs 12 or 3.9% from its previous closing of Rs 307.4 on the BSE. The company has received a Complete Response Letter (CRL) from the USFDA for the New Drug Application (NDA) for Xelpros, Latanoprost BAK-free eyedrops.

The CRL references the recent inspection of the Sun Pharmaceutical Industries Ltd.'s Halol manufacturing site by USFDA and indicates that satisfactory resolution of the deficiencies identified during the inspection is required before the final approval of Xelpros.

The scrip opened at Rs 313 and has touched a high and low of Rs 328.15 and Rs 313 respectively. So far 858932 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 7589.93 crore.

The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 414.8 on 05-Aug-2016 and a 52 week low of Rs 243.43 on 25-Feb-2016. Last one week high and low of the scrip stood at Rs 316.2 and Rs 305.5 respectively. The promoters holding in the company stood at 66.93 % while Institutions and Non-Institutions held 8.45 % and 24.62 % respectively. The stock is currently trading below its 200 DMA.
or Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717